Ardsley Advisory Partners’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Ardsley Advisory Partners’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-21	Closed	-$75K	–	198
2020 Q3	$75K	Hold	21	–	–	0.01%	138
2020 Q2	$81K	Buy	21 +3	+17%	+$9.96K	0.02%	124
2020 Q1	$34K	Buy	18 +5	+38%	+$18.6K	0.01%	96
2019 Q4	$67K	Hold	13	–	–	0.01%	144
2019 Q3	$46K	Hold	13	–	–	0.01%	129
2019 Q2	$110K	Buy	13 +3	+30%	+$31.6K	0.02%	140
2019 Q1	$134K	Buy	10 +9	+900%	+$146K	0.03%	123
2018 Q4	$29K	Hold	1	–	–	0.01%	102
2018 Q3	$31K	Buy	+1	New	+$36.8K	﹤0.01%	150

Other funds holding SEEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ardsley Advisory Partners's SEEL Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2020, closing a stake of 21 shares — an estimated $75K sold.

Ardsley Advisory Partners first reported a position in SEEL in Q3 2018 and held it in 9 quarters. The position peaked at $134K in Q1 2019. 26 funds tracked by Wall St. Rank hold SEEL as of Q4 2020.

Ardsley Advisory Partners reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 21 Seelos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $75K.
Ardsley Advisory Partners first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 9 quarters.
Ardsley Advisory Partners's Seelos Therapeutics, Inc. Common Stock position peaked at $134K in Q1 2019.
26 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.